Compare Enphase Energy Inc (ENPH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs TransMedics Group Inc — how do they compare? Enphase Energy Inc trades at $32.7 (market cap $4.35B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Enphase Energy Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 5,068,595). Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and TransMedics Group Inc for 24 Days on average.
| ENPH | TMDX | |
|---|---|---|
Market Cap | $4.35B | $2.74B |
Volume | 5,068,595 | 949,331 |
Sector | Energy | Health |
52-Week High | $72.33 | $150.42 |
52-Week Low | $26.12 | $61.99 |
Typical Hold Time | 72 Days | 24 Days |
Enterprise Value | $3.99B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.81, down 2.06% on the day, with a bearish technical signal from moving averages and mixed recent earnings. The company reported revenue of $1.47B and net income of $172.13M for 2025, with a P/E ratio of 32.58. Recent news highlights product approvals and manufacturing milestones for AI data center power solutions, though the solar sector faces headwinds from high borrowing costs.
The outlook is cautious; while analyst consensus is a Buy with a $42.90 price target, near-term risks include sector volatility and recent earnings misses. Long-term opportunities hinge on execution in the energy technology and AI infrastructure markets, but investors should weigh competitive pressures and macroeconomic factors affecting solar project financing.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
